Keyword: Japan

Amgen heads into an FDA adcomm for new osteoporosis drug Evenity next week comforted by a first approval for the bone-building drug in Japan.

Chugai has the phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder next year.

Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply its investment pool sixfold to $300 million.

Japan-based Modulus Discovery raised $7.2 million in series A funds that will be used to bolster its R&D platform efforts.

HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies.

Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.

Sirt2, an enzyme long of interest to scientists studying metabolism and aging, seems to mediate the process by which the liver processes glucose.

Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.

Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.